Pathophysiology of the chronic kidney disease - Mineral bone disorder

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 4, 2015, Pages 303-309

  Hruska, Keith A ^a   Seifert, Michael ^a,b   Sugatani, Toshifumi ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activin; Chronic kidney disease mineral bone disorder; Dickkopf 1; Fibroblast growth factor 23; Klotho; Parathyroid hormone; Renal osteodystrophy; Vascular calcification

Indexed keywords

ACTIVIN A; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MINERAL;

BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISTAL TUBULE; KIDNEY FIBROSIS; MYOFIBROBLAST; NONHUMAN; OSTEOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RENAL OSTEODYSTROPHY; REVIEW; SIGNAL TRANSDUCTION; SODIUM ABSORPTION; SYSTEMS BIOLOGY; VASCULAR SMOOTH MUSCLE CELL; VITAMIN D DEFICIENCY; WNT SIGNALING PATHWAY; ANIMAL; BONE DISEASES, METABOLIC; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM;

ANIMALS; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; HUMANS; MINERALS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84942742623     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000132     Document Type: Review

References (73)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003;108:2154-2169.
2. Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and & intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 2015;87:649-659. This article establishes that mild-to-moderate diabetic nephropathy increases cardiovascular risk through stimulation of atherosclerosis.
3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
5. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
6. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl J Med 2008;359:584-592.
7. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-885.
8. Matsushita K, Sang Y, Ballew SH, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Neph 2014;26:439-447.
9. Dalal M, Sun K, Cappola AR, et al. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011;165:797-803.
10. Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral & bone disorder stimulates vascular calcification. Kidney Int 2014;85:142-150. This article characterizes the CKD-MBD in early CKD in a translational model of type 2 diabetes equivalent to human stage 2 CKD, consisting of vascular smooth muscle dedifferentiation, vascular calcification, loss of renal klotho, elevation of FGF23 and renal osteodystrophy. PTH, Pi, Ca, and calcitriol are normal at this stage.
11. Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone 2009;45:1161-1168.
12. Fang Y, Zhang Y, Mathew S, et al. Early chronic kidney disease (CKD) stimulates vascular calcification (VC) and decreased bone formation rates prior to positive phosphate balance. J Am Soc Nephrol 2009;20:36A.
13. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124-136.
14. Fang Y, Ginsberg C, Seifert M, et al. CKD-induced wingless/integration1 & inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014;25:1760-1763. This article is the first discovery of a renal repair factor, a Wnt inhibitor-Dkk1, causing extrarenal disease, showing that CKD directly causes cardiovascular disease. The surprising effects of Dkk1 neutralization suggested that CKD caused endothelial, mesenchymal transition, confirmed in the Agapova et al. study [37&].
15. De Oliveira RB, Graciolli FG, Dos Reis LM, et al. Disturbances of Wnt/bcatenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant 2013;28:2510-2517.
16. Sabbagh Y. Repression of osteocyte Wnt/[beta]-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012;27:1757-1772.
17. Surendran K, McCaul SP, Simon TC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol 2002;282:F431-F441.
18. Surendran K, Schiavi S, Hruska KA. Wnt-dependent-b-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005;16:2373-2384.
19. Maeshima A, Nojima Y, Kojima I. The role of the activin-follistatin system in the developmental and regeneration processes of the kidney. Cytokine Growth Factor Rev 2001;12:289-298.
20. Terada Y, Tanaka H, Okado T, et al. Expression and function of the developmental gene wnt-4 during experimental acute renal failure in rats. J Am Soc Nephrol 2003;14:1223-1233.
21. Kawakami T, Ren S, Duffield JS. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol 2013;229:221-231.
22. Rinkevich Y, Montoro Daniel T, Contreras-Trujillo H, et al. In vivo clonal analysis reveals lineage-restricted progenitor characteristics in mammalian kidney development, maintenance, and regeneration. Cell Rep 2014;7:1270-1283.
23. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the á-catenin/TCF pathway. Oncogene 2004;23:8520-8526.
24. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006;25:7469-7481.
25. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-414.
26. Chamorro MN, Schwartz DR, Vonica A, et al. FGF-20 and DKK1 are transcriptional targets of b-catenin and FGF-20 is implicated in cancer and development. EMBO J 2004;24:73-84.
27. Gonzalez-Sancho JM, Aguilera O, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of [beta]-catenin//TCF and is downregulated in human colon cancer. Oncogene 2004;24:1098-1103.
28. Al-Aly Z, Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-{alpha} dependent signals in diabetic ldlr/mice. Arterioscler Thromb Vasc Biol 2007;27:2589-2596.
29. Shao JS, Cheng SL, Pingsterhaus JM, et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115:1210-1220.
30. Cheng S-L, Shao J-S, Behrmann A, et al. Dkk1 and Msx2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol 2013;33:1679-1689.
31. Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995;77:1-6.
32. Camenisch TD, Molin DGM, Person A, et al. Temporal and distinct TGFb ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002;248:170-181.
33. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-961.
34. Moore-Morris T, Guimarães-Camboa N, Banerjee I, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest 2014;124:2921-2934.
35. Cooley BC, Nevado J, Mellad J, et al. TGF-b signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med 2014;6:227ra234. This article establishes EndMT in neointimal formation, which we have shown to be stimulated in CKD. It also shows that the smad pathway activated by activin is involved.
36. Ying S-Y. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 1988;9:267-293.
37. Agapova OA, Fang Y, Sugatani T, et al. Kidney disease produced circulating & renal repair factors cause vascular disease. JASN 2015. [Submitted] This article is the first demonstration that CKD increases circulating activin levels and vascular activin receptor type 2A signaling producing vascular effects related to activin and Wnt signaling. Activin in the kidney stimulates Wnt signaling producing increased circulating Dkk1. This produces a complex systemic effect of Wnt inhibition and activin signaling.
38. Seifert ME, De Las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in the early chronic kidney disease. Amer J Nephrol 2013;38:158-167.
39. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-348.
40. Liu S, Tang W, Zhou J, et al. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. AJP Endocrinol Metab 2007;293:E1636-E1644.
41. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378.
42. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956-966.
43. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 2007;18:2600-2608.
44. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
45. Andrukhova O, Slavic S, Smorodchenko A, et al. FGF23 regulates renal & sodium handling and blood pressure. EMBO Mol Med 2014;6:744-759. This article and [47&] raise the question of the mechanism of aklotho actions as indirect/coreceptor for FGF23 or direct, through its gluronidase and siladase activities.
46. Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, et al. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade. Am J Kidney Dis 2015;65:259-266.
47. Andrukhova O, Smorodchenko A, Egerbacher M, et al. FGF23promotes renal & calcium reabsorption through the TRPV5 channel. EMBO J 2014;33:229-246. doi: 10.1002/embj.201284188. [Epub ahead of print] This article and [45&] raise the question of the mechanism of aklotho actions as indirect/coreceptor for FGF23 or direct, through its gluronidase and siladase activities.
48. Chang Q, Hoefs S, Van Der Kemp AW, et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005;310:490-493.
49. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120-6123.
50. Chen C-D, Podvin S, Gillespie E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci 2007;104:19796-19801.
51. Sakan HNK, Asai O, Imura A, Tanaka T, et al. Reduced renal a-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS ONE 2014;9:e86301.
52. Smith RC, O'Bryan LM, Farrow EG, et al. Circulating aKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012;122:4710-4715.
53. Hu M-C, Shi M, Zhang J, et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010;78:1240-1251.
54. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH: double agents at the heart of CKD. Nephrol Dial Transpl 2012;27:1715-1720.
55. Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005;16:917-928.
56. Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in chronic kidney disease. J Am Soc Nephrol 2008;19:1092-1105.
57. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-157.
58. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and posttranscriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998;273:5253-5259.
59. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2279.
60. Isakova T, Barchi-Chung A, Enfield G, et al. Effects of dietary phosphate restriction and lanthanum carbonate on FGF23 in CKD. Clin J Am Soc Nephrol 2013;8:1009-1018.
61. Prié D, Friedlander G. Reciprocal Control of 1, 25-Dihydroxyvitamin D and FGF23 Formation Involving the FGF23/Klotho System. ClinJ AmSoc Nephrol 2010;5:1717-1722.
62. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of the CKD-MBD. Chapter 4.1: treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 2009;76:S50-S99.
63. Naveh-Many T, Marx R, Keshet E, et al. Regulation of 1, 25-dihydroxyvitamin D3 receptor gene expression by 1, 25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990;86:1968-1975.
64. Meir T, Durlacher K, Pan Z, et al. Parathyroid hormone activates the orphan & nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 2014;86:1106-1115. This article establishes the mechanism of the relationship between PTH and FGF23 in the osteocyte.
65. Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol 2013;33:169-179.
66. Moe SM, Abdalla S, Chertow GM, et al. Effects of cinacalcet on fracture events in patients receiving Hemodialysis: the EVOLVE trial. J Am Soc Nephrol 2014; doi: 10.1681/ASN.2014040414. [Epub ahead of print]
67. Malluche HH, Porter DS, Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol 2013;9:671-680.
68. Cunningham J, Sprague S, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566-571.
69. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-1093.
70. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-1121.
71. Ix JH, Katz R, De Boer IH, et al. Association of chronic kidney disease with the spectrum of ankle brachial index: the cardiovascular health study. J Am Coll Cardiol 2009;54:1176-1184.
72. Moe SM, Chen NX. Pathophysiology of vascular calcification inchronic kidney disease. Circ Res 2004;95:560-567.
73. Diarra D. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163.